Pulmonary metastasectomy in solid tumors: a single-center experience at a tertiary referral center in the Middle East.
7 affiliations
- 1Department of Surgery, King Hussein Cancer Center, Queen Rania Street, Amman, 11941, Jordan.
- 2Department of Surgery, King Hussein Cancer Center, Queen Rania Street, Amman, 11941, Jordan. [email protected].
- 3Faculty of Medicine, University of Jordan, Amman, Jordan.
- 4Department of Anesthesia, King Hussein Cancer Center, Amman, Jordan.
- 5Department of Surgery, Specialty Hospital, Amman, Jordan.
- 6Department of Radiology, King Hussein Cancer Center, Amman, Jordan.
- 7Department of Thoracic Surgery, Leeds Teaching Hospitals NHS Trust, West Yorkshire, UK.
Abstract
Background
Despite advances in systemic therapy, pulmonary metastasectomy remains a key option for selected patients with metastatic solid tumors, offering long-term survival. Prognosis is influenced by many factors including disease-free interval and metastatic burden. This study evaluates survival outcomes and prognostic factors in a mixed-tumor cohort from a Middle Eastern tertiary cancer center.Methods
This retrospective cohort study included all patients who underwent pulmonary metastasectomy for solid tumors at King Hussein Cancer Center between October 2014 and December 2024. Demographic, clinical, imaging, surgical, pathological, and follow-up data were collected from electronic medical records. Overall survival (OS) and pulmonary recurrence-free survival (P-RFS) were estimated using Kaplan-Meier analysis, and prognostic factors were assessed using Cox proportional hazards models. Analyses were performed using SPSS version 27.Results
A total of 236 patients underwent 371 procedures. The mean follow-up was 31.9 months (95% CI:28.3-35.3). Median OS was 3.99 years (95% CI:2.69-5.28), with a 5-year OS rate of 42.0%. Mean P-RFS was 6.81 years (95% CI: 6.16-7.46), with the median not reached. On univariable analysis, worse OS was associated with metastatic lesion size ≥ 3 cm, bilateral metastases, thoracotomy, longer hospital stay, and increased tumor burden. R0 resection and DFI ≥ 12 months were protective. In multivariable analysis, independent predictors of worse OS were metastatic lesion size ≥ 3 cm (HR: 1.827, p = 0.015) and DFI < 12 months (HR for ≥ 12 months: 0.515, p = 0.002). Patients with colorectal cancer demonstrated numerically longer overall survival and lower pulmonary recurrence rates than patients with sarcoma (5-year OS: 44.8% vs. 32.2%; pulmonary recurrence: 18.8% vs. 34.4%). However, tumor type was not significantly associated with overall survival in univariable Cox regression analysis.Conclusion
Pulmonary metastasectomy is an important treatment option for patients with lung metastasis from different solid tumors that provides durable long-term and pulmonary recurrence-free survival in appropriately selected patients. Longer DFI and smaller metastatic lesion size independently predict improved outcomes.
Related
- Pediatric Brain Tumors: A Clinicopathological Study and Assessment of Caregiver Quality of Life at a Tertiary Neurosurgical Referral Center in Northern India
- Clinical manifestations, genetic characteristics and laboratory markers of patients with epidermolysis bullosa: a single tertiary referral center experience
- Sentinel Lymph Node Mapping in Endometrial Cancer: Experience from a Tertiary Referral Center in Türkiye
- PANCREATIC NEUROENDOCRINE TUMORS: CLINICOPATHOLOGICAL ANALYSIS AND POSTOPERATIVE SURVIVAL FOLLOWING SURGICAL RESECTION-A DECADE OF EXPERIENCE AT A TERTIARY UNIVERSITY HOSPITAL.
- Survival after pulmonary metastasectomy for pancreatobiliary carcinomas: insights from a nationwide multicenter database
BibTeX
@article{ghanayem2026pulmonary,
title = {{Pulmonary metastasectomy in solid tumors: a single-center experience at a tertiary referral center in the Middle East.}},
author = {Mohammad B Ghanayem and Riad Abdel Jalil and Alzahra'a Al Matairi and Ahed El-Edwan and Leen N Yousef and Saif Aburabie and Imad Alnimer and Azza Gharaibeh and Ahmad Abu-Shanab},
journal = {Journal of cardiothoracic surgery},
year = {2026},
month = aug,
doi = {10.1186/s13019-026-04522-x},
url = {https://europepmc.org/article/MED/42963788},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Pulmonary metastasectomy in solid tumors: a single-center experience at a tertiary referral center in the Middle East.
AU - Mohammad B Ghanayem
AU - Riad Abdel Jalil
AU - Alzahra'a Al Matairi
AU - Ahed El-Edwan
AU - Leen N Yousef
AU - Saif Aburabie
AU - Imad Alnimer
AU - Azza Gharaibeh
AU - Ahmad Abu-Shanab
PY - 2026
DA - 2026/08/04
JO - Journal of cardiothoracic surgery
DO - 10.1186/s13019-026-04522-x
UR - https://europepmc.org/article/MED/42963788
AB - Background Despite advances in systemic therapy, pulmonary metastasectomy remains a key option for selected patients with metastatic solid tumors, offering long-term survival. Prognosis is influenced by many factors including disease-free interval and metastatic burden. This study evaluates survival outcomes and prognostic factors in a mixed-tumor cohort from a Middle Eastern tertiary cancer center.Methods This retrospective cohort study included all patients who underwent pulmonary metastasectomy for solid tumors at King Hussein Cancer Center between October 2014 and December 2024. Demographic, clinical, imaging, surgical, pathological, and follow-up data were collected from electronic medical records. Overall survival (OS) and pulmonary recurrence-free survival (P-RFS) were estimated using Kaplan-Meier analysis, and prognostic factors were assessed using Cox proportional hazards models. Analyses were performed using SPSS version 27.Results A total of 236 patients underwent 371 procedures. The mean follow-up was 31.9 months (95% CI:28.3-35.3). Median OS was 3.99 years (95% CI:2.69-5.28), with a 5-year OS rate of 42.0%. Mean P-RFS was 6.81 years (95% CI: 6.16-7.46), with the median not reached. On univariable analysis, worse OS was associated with metastatic lesion size ≥ 3 cm, bilateral metastases, thoracotomy, longer hospital stay, and increased tumor burden. R0 resection and DFI ≥ 12 months were protective. In multivariable analysis, independent predictors of worse OS were metastatic lesion size ≥ 3 cm (HR: 1.827, p = 0.015) and DFI < 12 months (HR for ≥ 12 months: 0.515, p = 0.002). Patients with colorectal cancer demonstrated numerically longer overall survival and lower pulmonary recurrence rates than patients with sarcoma (5-year OS: 44.8% vs. 32.2%; pulmonary recurrence: 18.8% vs. 34.4%). However, tumor type was not significantly associated with overall survival in univariable Cox regression analysis.Conclusion Pulmonary metastasectomy is an important treatment option for patients with lung metastasis from different solid tumors that provides durable long-term and pulmonary recurrence-free survival in appropriately selected patients. Longer DFI and smaller metastatic lesion size independently predict improved outcomes.
SN - 1749-8090
ER -